Amicus Therapeutics Stock Performance
| FOLD Stock | USD 14.25 0.04 0.28% |
Amicus Therapeutics holds a performance score of 19 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.8, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Amicus Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Amicus Therapeutics is expected to be smaller as well. Use Amicus Therapeutics value at risk, kurtosis, and the relationship between the sortino ratio and semi variance , to analyze future returns on Amicus Therapeutics.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Amicus Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak essential indicators, Amicus Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
Five Day Return 0.42 | Year To Date Return 53.06 | Ten Year Return 51.76 | All Time Return (1.25) |
1 | Cytokinetics Gains 11.4 percent in a Week Is There More Room for Growth | 11/13/2025 |
2 | David Michael Clark Sells 25,643 Shares of Amicus Therapeutics Stock | 11/28/2025 |
3 | Acquisition by Samantha Prout of 32193 shares of Amicus Therapeutics subject to Rule 16b-3 | 12/01/2025 |
4 | Disposition of 11000 shares by Ellen Rosenberg of Amicus Therapeutics at 5.13 subject to Rule 16b-3 | 12/10/2025 |
5 | Wall Street Analysts See a 60.61 percent Upside in Amicus Therapeutics Can the Stock Really Move This High | 12/12/2025 |
6 | Citigroup Initiates Coverage on Amicus Therapeutics | 12/17/2025 |
7 | STAT BioMarin to buy Amicus Therapeutics for 4.8B, bringing together rare disease biotechs | 12/19/2025 |
8 | BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for 4.8B | 12/22/2025 |
9 | Amicus Therapeutics Nasdaq Futures Clinical Strategy | 12/23/2025 |
| Begin Period Cash Flow | 250.1 M | |
| Total Cashflows From Investing Activities | -560 K |
Amicus Therapeutics Relative Risk vs. Return Landscape
If you would invest 788.00 in Amicus Therapeutics on September 30, 2025 and sell it today you would earn a total of 637.00 from holding Amicus Therapeutics or generate 80.84% return on investment over 90 days. Amicus Therapeutics is currently generating 1.0208% in daily expected returns and assumes 4.2194% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Amicus, and 80% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Amicus Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amicus Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Amicus Therapeutics, and traders can use it to determine the average amount a Amicus Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2419
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | FOLD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Amicus Therapeutics is performing at about 19% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amicus Therapeutics by adding it to a well-diversified portfolio.
Amicus Therapeutics Fundamentals Growth
Amicus Stock prices reflect investors' perceptions of the future prospects and financial health of Amicus Therapeutics, and Amicus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amicus Stock performance.
| Return On Equity | -0.0687 | ||||
| Return On Asset | 0.0261 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 4.59 B | ||||
| Shares Outstanding | 309.3 M | ||||
| Price To Earning | (9.18) X | ||||
| Price To Book | 19.13 X | ||||
| Price To Sales | 7.36 X | ||||
| Revenue | 528.29 M | ||||
| Gross Profit | 537.49 M | ||||
| EBITDA | 29.39 M | ||||
| Net Income | (56.11 M) | ||||
| Cash And Equivalents | 386.84 M | ||||
| Cash Per Share | 1.38 X | ||||
| Total Debt | 443.64 M | ||||
| Debt To Equity | 2.60 % | ||||
| Current Ratio | 3.02 X | ||||
| Book Value Per Share | 0.75 X | ||||
| Cash Flow From Operations | (33.89 M) | ||||
| Earnings Per Share | (0.04) X | ||||
| Market Capitalization | 4.41 B | ||||
| Total Asset | 785.03 M | ||||
| Retained Earnings | (2.74 B) | ||||
| Working Capital | 356.03 M | ||||
| Current Asset | 216.6 M | ||||
| Current Liabilities | 73.62 M | ||||
About Amicus Therapeutics Performance
By analyzing Amicus Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Amicus Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Amicus Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Amicus Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 818.91 | 532.30 | |
| Return On Tangible Assets | (0.10) | (0.10) | |
| Return On Capital Employed | 0.04 | 0.04 | |
| Return On Assets | (0.07) | (0.07) | |
| Return On Equity | (0.29) | (0.30) |
Things to note about Amicus Therapeutics performance evaluation
Checking the ongoing alerts about Amicus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Amicus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Amicus Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 528.29 M. Net Loss for the year was (56.11 M) with profit before overhead, payroll, taxes, and interest of 537.49 M. | |
| Amicus Therapeutics currently holds about 386.84 M in cash with (33.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38. | |
| Amicus Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from kalkinemedia.com: Amicus Therapeutics Nasdaq Futures Clinical Strategy |
- Analyzing Amicus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amicus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Amicus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amicus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amicus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amicus Therapeutics' stock. These opinions can provide insight into Amicus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stocks Directory Find actively traded stocks across global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |